Christian Angermayerthe founder and CEO of Apeiron Investment Groupadds shares of more than $1,000,000 ATAI Life Sciences NV ATAI. Angermayer has laid out the reasons for his decision to increase his investment in a blog post LinkedIn.

What happened: Atai is one of the leaders in the psychedelic space, aiming to transform the way mental illness is treated through therapies based on substances like psilocybin and MDMA. The therapies are designed to help patients cope with mental disorders such as depression and PTSD.

“I believe that atai Life Sciences is the greatest entrepreneurial opportunity that I have ever encountered as an investor,” Angermayer wrote in his blog post. “I truly believe this company has an incredible future and is well positioned to make a positive and meaningful difference in addressing one of the greatest challenges facing humanity – the escalating mental health crisis.”

Angermayer was already a major investor in Atai, owning more than 10% of the company. But in the blog post, Angermayer says he has confidence in THE management, is undeterred by high interest rates, and believes weak stock performance presents ample opportunity.

While it may sound strange to some people, medications derived from psychedelic drugs like psilocybin and MDMA have shown promising results in clinical trials. In fact, in one study, two-thirds of PTSD patients received treatment with MDMA no longer met the clinical definition of PTSD until the end of the process.

Angermayer lists market opportunities, patents, regulations and more in his 14 reasons to strengthen his position as an Atai. Accordingly whale wisdom, Apeiron now owns more than 30,000,000 shares of Atai. Read Angermeyers in full Blog post, click here.